Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Cornetta

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 15, 2022
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trialsKenneth Cornetta, Jing Yao, Kimberley House, et al.
The New England Journal of Medicine|October 15, 2025
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase DeficiencyClaire Booth, Katelyn Masiuk, Konstantinos Vazouras, et al.
Nature|September 17, 2010
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaMarina Cavazzana-Calvo, Emmanuel Payen, Olivier Negre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanomaThinle Chodon, Begoña Comin-Anduix, Bartosz Chmielowski, et al.
Blood|May 11, 2021
Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiencyBryanna Reinhardt, Omar Habib, Kit L Shaw, et al.
The Journal of Clinical Investigation|March 28, 2017
Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiencyKit L Shaw, Elizabeth Garabedian, Suparna Mishra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2018
IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune SystemCristina Puig-Saus, Giulia Parisi, Angel Garcia-Diaz, et al.
The New England Journal of Medicine|May 11, 2021
Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase DeficiencyDonald B Kohn, Claire Booth, Kit L Shaw, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 15, 2022
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trialsKenneth Cornetta, Jing Yao, Kimberley House, et al.
The New England Journal of Medicine|October 15, 2025
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase DeficiencyClaire Booth, Katelyn Masiuk, Konstantinos Vazouras, et al.
Nature|September 17, 2010
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemiaMarina Cavazzana-Calvo, Emmanuel Payen, Olivier Negre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2014
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanomaThinle Chodon, Begoña Comin-Anduix, Bartosz Chmielowski, et al.
Blood|May 11, 2021
Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiencyBryanna Reinhardt, Omar Habib, Kit L Shaw, et al.
The Journal of Clinical Investigation|March 28, 2017
Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiencyKit L Shaw, Elizabeth Garabedian, Suparna Mishra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2018
IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune SystemCristina Puig-Saus, Giulia Parisi, Angel Garcia-Diaz, et al.
The New England Journal of Medicine|May 11, 2021
Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase DeficiencyDonald B Kohn, Claire Booth, Kit L Shaw, et al.
Pageof 9